(redirected from Dry eye syndrome)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Dry eye syndrome: Restasis


Dryness and thickening of the conjunctiva, sometimes following chronic conjunctivitis, disease of the lacrimal apparatus, or vitamin A deficiency.



an affection of the eyes expressed in dryness of the conjunctiva and cornea. It arises as a result of disturbance of tear secretion and chiefly of trophic disturbances. One of the immediate causes of xerophthalmia is avitaminosis A; it may arise in children when there are severe gastrointestinal diseases. The most frequent causes of xerophthalmia are trachoma, pemphigus, and chemical burns of the eyes. It is manifested by a sensation of dryness and pain in the eyes and heaviness of the eyelids; the cornea becomes cloudy and may undergo irreversible cicatricial changes. Vision is decreased.

Xerophthalmia is treated by medication; good results are obtained by transplanting the excretory duct of the parotid gland to the conjunctival sac to restore moisture to the eye.

References in periodicals archive ?
RGN-259 has been shown to reduce corneal damage associated with dry eye syndrome in two animal models when compared to both positive and negative controls.
OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced that treatment and follow-up have been completed on 69 patients in the Company's Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome, five more than the number of evaluable patients contemplated in the trial's protocol.
Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis; Cationorm(R), a CE marking product for dry eye relief; and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome.
The most common causes of dry eye syndrome are hormonal changes in menopause, ocular surgery, and environmental factors such as dust and pollutants.
Human data have been reported and published indicating that RGN-259 can successfully heal ocular surface defects, which most often occur as a result of dry eye syndrome and particularly in patients with moderate to severe dry eye.
Dry eye syndrome cannot be cured, but symptoms can be controlled.
Lantibio's lead product, Moli1901, is currently in clinical development in the United States for the treatment of dry eye syndrome in Phase II.
Dry eye syndrome is linked to a quantitative or qualitative deficit of tears and characterized by a lasting and painful ocular discomfort, which severely debilitates sufferers.
The authors analysis points out that the current competition in the dry eye syndrome therapeutics market is weak, and available treatment options have been moderately successful in meeting market demand.
G-treeBNT recently received permission from the Korean Ministry of Food and Drug Safety (MFDS) to begin its Phase IIb/III clinical trial for dry eye syndrome in Korea.
announced today that the United States Food and Drug Administration (FDA) accepted an Investigational New Drug Application (IND) for the human clinical testing of Moli1901 for the treatment of dry eye syndrome.
Dry Eye Syndrome, which affects both women and men, often goes undiagnosed and if left untreated, can lead to long-term complications.